Objective: To study the expression level and clinical significance of Gli1 gene in patients with myelodysplastic syndrome(MDS).
Methods: The positive rate of bone marrow CD34+ cells was detected by flow cytometry in 53 patients with MDS.Magnetic beads were used to separate CD34+ cells. The expression of Gli1 on CD34+ cells was detected by RT-qPCR, 25 patients with iron deficiency anemia were selected as controls. The relationship of Gli1 expression with clinical characteristics were analyzed.
Results: The expression of Gli1 in patients with MDS (0.73±1.26) was significantly higher than that in the control group (0.07±0.46) (P＜0.05). The expression of Gli1 significantly correlated with platelet count, chromosome grouping and IPSS risk stratification (P＜0.05). The median overall survival time of patients in high and low expression groups were 7 and 20 months respectively (P＜0.05). Multivariate analysis showed that Gli1 and chromosome grouping were 2 independent poor prognostic factors (P＜0.05).
Conclusion: The expression of Gli1 is high in MDS. Abnormal expression of Gli1 positively correlates with clinical characteristics and prognosis of patients.Gli1 may be involved in the occurrence and development of MDS.
题目: 骨髓增生异常综合征患者中Gli1的表达水平及其临床意义.
目的: 探讨Shh信号通路关键因子Gli1在骨髓增生异常综合征（MDS）患者中的表达水平及其临床意义.
方法: 对53例MDS患者采用流式细胞术检测骨髓CD34+ 阳性率，磁珠分选CD34+ 细胞，再用荧光实时定量 PCR法检测CD34+ 上Gli1基因的表达，以25例缺铁性贫血患者作对照，分析Gli1表达与MDS患者临床特征和预后的关系及其意义.
结果: MDS患者中Gli1表达水平（0.73±1.26）明显高于对照组（0.07±0.46)(P＜0.05)；Gli1表达水平与血小板计数、染色体分组和IPSS危险度分层均相关(P＜0.05）；Gli1高表达和低表达组患者中位生存时间[JP2]分别为7个月和20个月(P＜0.05)。多因素分析显示，Gli1和染色体分组是2个独立的不良因素（均P＜0.05）.
结论: Gli1在MDS中高表达，并与患者的临床特征及预后存在显著相关性，Gli1可能参与MDS的发生及发展.